Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 16Recurrence 3Lymphoma, T-Cell, Peripheral 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Immunoglobulin Light-chain Amyloidosis 2Triple Negative Breast Neoplasms 1Proteostasis Deficiencies 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Neoplasms, Plasma Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hematologic Neoplasms 1Chromosome 17 deletion 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Burkitt Lymphoma 1Breast Neoplasms 1Amyloidosis 1Alzheimer Disease 1

Interventions

Melphalan 16Dexamethasone 15Bortezomib 11Peripheral Blood Stem Cell Transplantation 9Lenalidomide 9fludarabine phosphate 8Calcium Dobesilate 7pomalidomide 5fludarabine 5Busulfan 5carfilzomib 4Radiotherapy 4Prednisone 4Cyclophosphamide 4liposomal doxorubicin 3daratumumab 3Tacrolimus 3Mycophenolic Acid 3Methotrexate 3Filgrastim 3Cyclosporine 3Arsenic Trioxide 3Alemtuzumab 3samarium Sm-153 lexidronam 2holmium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetrakis(methylenephosphonic acid) 2Whole-Body Irradiation 2Surveys and Questionnaires 2Pneumococcal Vaccines 2Granulocyte Colony-Stimulating Factor 2Bendamustine Hydrochloride 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms, Plasma Cell × ixazomib × Clear all
NCT02542657 2024-09-19

Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma

University of California, Davis

Phase 1/2 Active not recruiting
30 enrolled
Plasma cell

Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡